FDA approves Mylan's biosimilar of Roche's breast cancer treatment

Dec 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster breast cancer treatment Herceptin.

The FDA approved the treatment, Ogivri, for certain patients with breast or stomach cancer.

(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)